Cargando…

Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy

Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with very few treatment options. Although tumor-targeted nanomedicines hold great promise for the treatment of TNBC, the tumor microenvironment (TME) continues to be a major cause of failure in nanothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Huan, Xu, Jinshun, Gao, Binyang, Wang, Hong, Huang, Jianbo, Zhou, Jie, Yang, Rui, Yan, Feng, Peng, Yulan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636108/
https://www.ncbi.nlm.nih.gov/pubmed/34867360
http://dx.doi.org/10.3389/fphar.2021.750847
_version_ 1784608467762282496
author Zhang, Huan
Xu, Jinshun
Gao, Binyang
Wang, Hong
Huang, Jianbo
Zhou, Jie
Yang, Rui
Yan, Feng
Peng, Yulan
author_facet Zhang, Huan
Xu, Jinshun
Gao, Binyang
Wang, Hong
Huang, Jianbo
Zhou, Jie
Yang, Rui
Yan, Feng
Peng, Yulan
author_sort Zhang, Huan
collection PubMed
description Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with very few treatment options. Although tumor-targeted nanomedicines hold great promise for the treatment of TNBC, the tumor microenvironment (TME) continues to be a major cause of failure in nanotherapy and immunotherapy. To overcome this barrier, we designed a new synergistic cascade strategy (SCS) that uses mild hyperthermia and smart drug delivery system (SDDS) to alter TME resistance in order to improve drug delivery and therapeutic efficacy of TNBC. Methods: Mild hyperthermia was produced by microwave (MW) irradiation. SDDS were formulated with thermosensitive polymer-lipid nanoparticles (HA-BNPs@Ptx), composed of polymer PLGA, phospholipid DPPC, hyaluronic acid (HA, a differentiation-44-targeted molecule, also known as CD44), 1-butyl-3-methylimidazolium-L-lactate (BML, a MW sensitizer), and paclitaxel (Ptx, chemotherapy drug). 4T1 breast tumor-bearing mice were treated with two-step MW combined with HA-BNPs@Ptx. Tumors in mice were pretreated with first MW irradiation prior to nanoparticle injection to modify and promote TME and promoting nanoparticle uptake and retention. The second MW irradiation was performed on the tumor 24 h after the injection of HA-BNPs@Ptx to produce a synergistic cascade effect through activating BML, thus, enhancing a hyperthermia effect, and instantly releasing Ptx at the tumor site. Results: Multifunctional CD44-targeted nanoparticles HA-BNPs@Ptx were successfully prepared and validated in vitro. After the first MW irradiation of tumors in mice, the intratumoral perfusion increased by two times, and the nanoparticle uptake was augmented by seven times. With the second MW irradiation, remarkable antitumor effects were obtained with the inhibition rate up to 88%. In addition, immunohistochemical analysis showed that SCS therapy could not only promote tumor cell apoptosis but also significantly reduce lung metastasis. Conclusion: The SCS using mild hyperthermia combined with SDDS can significantly improve the efficacy of TNBC treatment in mice by modifying TME and hyperthermia-mediated EPR effects.
format Online
Article
Text
id pubmed-8636108
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86361082021-12-02 Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy Zhang, Huan Xu, Jinshun Gao, Binyang Wang, Hong Huang, Jianbo Zhou, Jie Yang, Rui Yan, Feng Peng, Yulan Front Pharmacol Pharmacology Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with very few treatment options. Although tumor-targeted nanomedicines hold great promise for the treatment of TNBC, the tumor microenvironment (TME) continues to be a major cause of failure in nanotherapy and immunotherapy. To overcome this barrier, we designed a new synergistic cascade strategy (SCS) that uses mild hyperthermia and smart drug delivery system (SDDS) to alter TME resistance in order to improve drug delivery and therapeutic efficacy of TNBC. Methods: Mild hyperthermia was produced by microwave (MW) irradiation. SDDS were formulated with thermosensitive polymer-lipid nanoparticles (HA-BNPs@Ptx), composed of polymer PLGA, phospholipid DPPC, hyaluronic acid (HA, a differentiation-44-targeted molecule, also known as CD44), 1-butyl-3-methylimidazolium-L-lactate (BML, a MW sensitizer), and paclitaxel (Ptx, chemotherapy drug). 4T1 breast tumor-bearing mice were treated with two-step MW combined with HA-BNPs@Ptx. Tumors in mice were pretreated with first MW irradiation prior to nanoparticle injection to modify and promote TME and promoting nanoparticle uptake and retention. The second MW irradiation was performed on the tumor 24 h after the injection of HA-BNPs@Ptx to produce a synergistic cascade effect through activating BML, thus, enhancing a hyperthermia effect, and instantly releasing Ptx at the tumor site. Results: Multifunctional CD44-targeted nanoparticles HA-BNPs@Ptx were successfully prepared and validated in vitro. After the first MW irradiation of tumors in mice, the intratumoral perfusion increased by two times, and the nanoparticle uptake was augmented by seven times. With the second MW irradiation, remarkable antitumor effects were obtained with the inhibition rate up to 88%. In addition, immunohistochemical analysis showed that SCS therapy could not only promote tumor cell apoptosis but also significantly reduce lung metastasis. Conclusion: The SCS using mild hyperthermia combined with SDDS can significantly improve the efficacy of TNBC treatment in mice by modifying TME and hyperthermia-mediated EPR effects. Frontiers Media S.A. 2021-11-15 /pmc/articles/PMC8636108/ /pubmed/34867360 http://dx.doi.org/10.3389/fphar.2021.750847 Text en Copyright © 2021 Zhang, Xu, Gao, Wang, Huang, Zhou, Yang, Yan and Peng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Huan
Xu, Jinshun
Gao, Binyang
Wang, Hong
Huang, Jianbo
Zhou, Jie
Yang, Rui
Yan, Feng
Peng, Yulan
Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy
title Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy
title_full Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy
title_fullStr Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy
title_full_unstemmed Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy
title_short Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy
title_sort synergistic cascade strategy based on modifying tumor microenvironment for enhanced breast cancer therapy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636108/
https://www.ncbi.nlm.nih.gov/pubmed/34867360
http://dx.doi.org/10.3389/fphar.2021.750847
work_keys_str_mv AT zhanghuan synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy
AT xujinshun synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy
AT gaobinyang synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy
AT wanghong synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy
AT huangjianbo synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy
AT zhoujie synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy
AT yangrui synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy
AT yanfeng synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy
AT pengyulan synergisticcascadestrategybasedonmodifyingtumormicroenvironmentforenhancedbreastcancertherapy